A prospective clinical trial of prolonged autologous erythropoietin (EPO) secretion from TARGTEPO in EPO-dependent end stage renal disease patients showed EPO independence for over 8 months

Category Primary study
JournalHaematologica
Year 2015
This article has no abstract
Epistemonikos ID: 61e7c1469d58d2d66367db56838a849b46bd3e2c
First added on: Feb 07, 2025